Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Zartra has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 31/07/2002
Authorisation details
| Product details | |
|---|---|
| Name |
Zartra
|
| Agency product number |
EMEA/H/C/000180
|
| Active substance |
imiquimod
|
| International non-proprietary name (INN) or common name |
imiquimod
|
| Therapeutic area (MeSH) |
Condylomata Acuminata
|
| Anatomical therapeutic chemical (ATC) code |
L03AX
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Laboratoires 3M Santé
|
| Revision |
0
|
| Date of issue of marketing authorisation valid throughout the European Union |
18/09/1998
|
| Contact address |
Laboratories 3M Sante
Boulevard de l'Oise F-95029 Cergy Pontoise Cedex France |
Product information
11/06/2002 Zartra - EMEA/H/C/000180 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Pharmacotherapeutic group
Immunostimulants
Therapeutic indication
Therapeutic indication
Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.